Abstract:Purpose: Overexpression of extracellular matrix metalloproteinase inducer (EMMPRIN), a member of the immunoglobulin family and a glycoprotein enriched on the surface of many types of tumor cells, has been reported to be linked to invasion, metastasis, growth, and survival of malignant cells. Cervical cancer, the second most prevalent cancer in women worldwide and the fifth leading cause of cancer deaths, responds to radiotherapy variably, with 30% of cases recurring after therapy. The purpose of this study was to determine whether expression of EMMPRIN affects the response of cervical cancer to radiation therapy, and whether this membrane protein can be used as a prognostic marker for cervical cancer.Experimental Design: The retrospective cohort study included 82 patients with invasive cervical cancer referred to the Department of Gynecologic Oncology at The Cancer Hospital of Fudan University (Shanghai) between 1991 and 2000. These patients were treated with brachytherapy at a dose of 15 Gy at point A before radical hysterectomy. Expression of EMMPRIN in cervical tumor specimens was examined by immunohistochemistry staining before and after brachytherapy and scored for both staining intensity and percentage of tumor cells stained. EMMPRIN immunoreactivity and clinicopathologic data were analyzed with respect to survival end points using univariate and multivariate approaches.Results: The frequency of EMMPRIN overexpression was 52.4% in primary cervical cancer. After brachytherapy, EMMPRIN overexpression was significantly reduced (13.4%) compared with corresponding tumor before brachytherapy (P = 0.032). EMMPRIN expression was associated with pelvic lymph node metastasis (P = 0.026) and reduction in primary tumor volume following brachytherapy (P = 0.008). Although EMMPRIN expression before or after brachytherapy did not correlate with tumor-specific survival, but increased expression of EMMPRIN following brachytherapy tended to predict poor outcomes by univariate survival analysis (P = 0.0008). In addition, lymph vascular space invasion, deep stromal invasion, and lymph node metastasis were significantly associated with poor prognosis. In multivariate analysis, the independent prognostic factors for tumor-specific survival included the decreased expression of EMMPRIN after brachytherapy (P = 0.002; hazard ratio, 0.339; 95% confidence interval, 0.172-0.672) as well as lymph node metastasis (P = 0.044; hazard ratio, 2.053; 95% confidence interval, 1.020-4.133).Conclusion: Expression of EMMPRIN was associated with a decrease in the reduction of cervical tumor following brachytherapy, and increased EMMPRIN expression after brachytherapy seemed to be an important predictor of poor survival in this patient cohort. Our study suggests that expression of EMMPRIN confers resistance to radiotherapy. Therefore, EMMPRIN expression in cervical cancer may be regarded both as a prognostic factor and a therapeutic target.

Up-regulated EMMPRIN/CD147 Protein Expression Might Play a Role in Colorectal Carcinogenesis and Its Subsequent Progression Without an Alteration of Its Glycosylation and Mrna Level

[Increased Expression of Extracellular Matrix Metalloproteinase Inducer Through Interaction Between Fibroblasts and Colonic Cancer Cells].

Effects of Fibroblasts-Colorectal Cancer Cells Interaction on EMMPRIN Expression in Colorectal Cancer Cells

LoVo Colon Carcinoma Cells Up-Regulate the Expression of EMMPRIN in Human Umbilical Vein Endothelial Cells

Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer

A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells.

The Significance of the Expression of Extracellular Matrix Metalloproteinase Inducer in Colorectal Cancer by Western Blot

Evaluation of EMMPRIN (CD147) Expression in Cervical Cancer: a Critical Role in Development and Progression

EMMPRIN regulates tumor growth and metastasis by recruiting bone marrow-derived cells through paracrine signaling of SDF-1 and VEGF

Gdf15 Promotes Emt And Metastasis In Colorectal Cancer

CTHRC1 Overexpression Predicts Poor Survival and Enhances Epithelial‐mesenchymal Transition in Colorectal Cancer

High incidence of EMMPRIN expression in human tumors

CD31 and D2-40 Contribute to Peritoneal Metastasis of Colorectal Cancer by Promoting Epithelial-Mesenchymal Transition

Epithelial Membrane Protein 2 and Inhibition of Epithelial Mesenchymal Transition by Interaction with Integrin Α5β1 and Induction Its Ubiquitination in Colon Cancer.

Expression and clinical significance of CD147 in genitourinary carcinomas.

EMMPRIN Expression As a Prognostic Factor in Radiotherapy of Cervical Cancer

Upregulation of EMR1 (ADGRE1) by Tumor-Associated Macrophages Promotes Colon Cancer Progression by Activating the JAK2/STAT1,3 Signaling Pathway in Tumor Cells

Potential regulation and prognostic model of colorectal cancer with extracellular matrix genes

Expression of CD147 and Matrix Metalloproteinase-11 in Colorectal Cancer and Their Relationship to Clinicopathological Features.

Mir-4775 Promotes Colorectal Cancer Invasion and Metastasis Via the Smad7/TGFβ-mediated Epithelial to Mesenchymal Transition

EFEMP2 Promotes Colon Cancer Cell Invasion and Growth Through the ERK1/2 Signaling Pathway.